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Jet injection provides a needle-free alternative to conventional 
subcutaneous administration of insulin. The jet injector admin-
isters insulin at a high velocity (typically >100 m/s) directly 
across the skin into the subcutaneous tissue, where it is dis-
persed in a spray-like pattern which facilitates its uptake into 
the circulation.1 We have previously shown, both in healthy 
volunteers and in patients with diabetes, that insulin absorp-
tion from the subcutaneous tissue is considerably enhanced 
when insulin is administered by a jet injector instead of a con-
ventional pen.2,3 This enhancement leads to a 40-50% advance-
ment in the time to reach the maximal glucose-lowering 
effect,2 a shorter duration of insulin action,3 and a faster cor-
rection of incidental marked hyperglycemia.4
For such an improved insulin effect to become clinically 
relevant, it needs to be reproducible. Large day-to-day vari-
ability in insulin effect hampers the achievement of optimal 
glycemic control5,6 and is associated with a diminished 
health-related quality of life, at least in patients with type 2 
diabetes.7 Variability in glucose-lowering effect can be 
explained by many parameters,6 but is in part determined by 
variability in the absorption of insulin from the subcutaneous 
area into the circulation. Prior studies have shown that the 
intraindividual variability of the metabolic effect of regular 
human insulin and of rapid-acting insulin analogues is still 
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Abstract
Background: Jet injection has been shown to accelerate the absorption and action of rapid-acting insulin. In this study, we 
compared the variability of absorption characteristics between jet injection and conventional administration of the rapid-
acting insulin analogue aspart.
Methods: A total of 30 healthy volunteers were enrolled in this randomized controlled blinded parallel study. On two test 
days, they received insulin aspart (0.2 units/kg body weight), either by jet injection or conventional pen, followed by a 6-hour 
euglycemic glucose clamp. Plasma glucose and insulin levels and glucose infusion rates were measured every 5 to 10 minutes 
to calculate the variability in pharmacological endpoints.
Results: Jet injection advanced the times until maximal insulin concentration (T-INS
max
) and glucose infusion rate (T-GIR
max
) 
by ~40% (both P < .01). The difference between the two test days for these endpoints did not differ between jet injection 
and conventional administration (T-INS
max
: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIR
max
: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = 
.66). The corresponding intraindividual coefficients of variation for injection by jet or conventional pen were 15.3 ± 3.3 and 
22.0 ± 4.6% (P = .25, P
variance
 = .044) for T-INS
max
 and 34.5 ± 5.1 and 21.2 ± 4.6% for T-GIR
max
 (P = .064, P
variance
 = .62). The 
variance in maximal insulin concentration was significantly less after conventional administration (P = .039). The variance in 
total glucose-lowering effect and total insulin exposure did not differ (P = .93 and P = .32)
Conclusion: Using a jet injector for insulin administration was associated with slightly altered variability in pharmacokinetic 
endpoints, but with about similar variability in pharmacodynamic endpoints compared to conventional administration. 
Variability in these endpoints remains considerable, regardless of the method of insulin administration.
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considerable, varying between 10-30%, when administered 
by needle and syringe.8
Studies published in the 1980s suggested about similar 
intraindividual variability for regular human insulin when 
injected by jet stream as compared to administration by nee-
dle and syringe.9,10 There are no data on the intraindividual 
variability of the pharmacology of rapid-acting insulin ana-
logues, when administered by jet injection. Also, previous jet 
injectors were criticized because they were cumbersome to 
handle and had a high propensity for errors, including “wet 
injections.”1 The current jet injector (ie, Insujet™) has been 
technically improved to assure better performance and easier 
handling by patients. The aim of this study was to examine 
the variability of the pharmacologic effect of the rapid-acting 
insulin analogue, aspart, when administered by jet injection 
as compared to that by a conventional pen.
Materials and Methods
Participants
Written informed consent was obtained from 30 healthy 
volunteers, who were recruited by advertisements via web-
sites. All patients were at least 18 years of age and had a 
body-mass index between 18-32 kg/m2. Patients were 
excluded if they had had a major vascular event (eg, myo-
cardial infarction, stroke, symptomatic peripheral artery 
disease, coronary bypass surgery, percutaneous coronary or 
peripheral artery angioplasty) in the previous 6 months, 
used medication other than oral contraceptives or had a 
medical condition that interfered with the study protocol. 
Pregnancy was excluded where appropriate. The study was 
approved by the institutional review board of the Radboud 
university medical center (identification code 2014-1346) 
and conducted according to Good Clinical Practice and the 
Helsinki Declaration. The study was registered with 
Clinicaltrials.gov under NCT02272296.
Experimental Study Design
Fifteen participants were randomized to the jet injector study 
arm and the other 15 participants to the conventional pen 
study arm, in blinded fashion and using a double-dummy 
design.2,3 All participants were examined on two study days, 
separated by a minimum of 1 day and a maximum of 7 days, 
during which they underwent a 6-hour euglycemic glucose 
clamp, as described previously.2 Briefly, all experiments 
started at 7:30 am and were conducted in a temperature-con-
trolled room (22-24°C), with the subjects in fasting condition 
and having abstained from smoking, alcohol use and caffeine 
use for at least 24 hours. A heated box at 55°C was used to 
arterialize venous blood.11 After obtaining baseline variables, 
insulin aspart (Novo Nordisk, Bagsvaerd, Denmark) was 
administered in a dose of 0.2 U per kg of body weight by 
either jet injection (Insujet, European Pharma Group bv, 
Schiphol-Rijk, the Netherlands) or by conventional pen with 
a 31 G, 6 mm needle (NovoPen IV, Novo Nordisk, Bagsvaerd, 
Denmark). The alternate device was used as placebo to 
administer an “empty” injection, that is, the device looked 
and felt like it delivered insulin but it contained no solution. 
All injections were given in the lower half of the abdomen by 
an independent research nurse. Both investigators and 
patients were blinded to which device contained the insulin. 
Randomization was done by a computer program with the 
use of blocks of two subjects.
After insulin administration, glucose infusion rate (GIR) 
was adjusted to maintain euglycemia, based on plasma glu-
cose levels, measured at the bedside at 5-min intervals during 
the first three hours of the study and at 10-min intervals for the 
following three hours. Blood for plasma insulin levels was 
sampled every 5 minutes during the first hour, every 15 min-
utes for the second hour, and every 30 minutes thereafter.
Analytical Procedures
Plasma glucose was measured by the glucose enzymatic-
amperometric method (Biosen C-line GP+, EKF-diagnostic 
GmbH, Barleben, Germany). Blood sampled for determina-
tion of plasma insulin levels was collected in lithium-heparin 
tubes. After centrifugation, the supernatant was stored at 
-80°C. Plasma insulin was measured by radioimmunoassay 
(RIA).11
Calculations and Statistical Analyses
The pharmacokinetic parameters were derived from 
plasma insulin levels and consisted of the time to maximal 
insulin concentration (T-INS
max
), the maximal insulin con-
centration (C-INS
max
), the area under the insulin concen-
tration curve (AUC
INS
) and the time until 50% of insulin 
absorption (T-INS
AUC50%
). For these parameters, we calcu-
lated the variance (ie, standard deviation squared), inter- 
and intraindividual coefficient of variation (CV) and mean 
day-to-day difference. The pharmacodynamic parameters 
were derived from the body-weight standardized GIR-
curves and included variance, inter- and intraindividual 
CV and mean difference in the time until maximal GIR 
(T-GIR
max
), reflecting the maximal glucose lowering 
effect, the maximal GIR (GIR
max
), the area under the GIR 
curve (AUC
GIR
), and the time until 50% of glucose dis-
posal (T-GIR
AUC50%
), as described previously.2 The vari-
ance in T-GIR
max
 was the primary endpoint. Mean outcomes 
measuring variance endpoints were log-transformed and 
tested using a one-way ANOVA with the device as between-
subject factor. Other endpoints were tested for normal dis-
tribution and compared with an independent samples t-test 
or Mann-Whitney U test, as appropriate. All statistical 
analyses were performed using SPSS (IBM SPSS Statistics 
for Windows, Version 20.0, IBM Corp, Armonk, NY). All 
data are expressed as means ± SEM, unless otherwise 
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indicated, and a P value of <.05 was considered statisti-
cally significant.
Results
Table 1 summarizes the baseline characteristics of the par-
ticipants. We screened and included 33 subjects. 
Replacements were required for two subjects who dropped 
out due to lack of time before the first experimental day, and 
for one participant for whom rescheduling the second test 
day (because of a technical problem with the Biosen glucose 
analyzer) proved impossible. The subjects were well matched 
for sex, age, BMI, and fasting glucose and insulin levels.
Glucose Clamp
Baseline glucose values did not differ between the 2 groups 
(table 1). Plasma glucose values during the glucose clamps 
were comparable on all test days (5.12 ± 0.03 and 5.12 ± 
0.03 mmol/l for jet injection versus 5.11 ± 0.03 and 5.11 ± 
0.02 mmol/l for conventional pen, P = .99). The CVs for 
glucose levels also showed no difference between the two 
groups (7.15 ± 0.54% and 7.67 ± 0.61% for jet injection 
versus 6.54 ± 0.40% and 6.49 ± 0.45% for the conventional 
pen, P = .31).
Pharmacokinetic Endpoints
After jet injection, insulin levels rose more rapidly and to 
higher levels as compared to conventional administration (P 
< .001 for both endpoints; Table 2, Figure 1a). The average 
time difference for T-INS
max
 between the two test days 
tended to be smaller for the jet injector (7.3 ± 1.9 versus 22.3 
± 6.3 min, P = .074) and the variance in T-INS
max
 was less 
after jet injection (P = .044). However, conventional pen 
administration was associated with smaller differences (P = 
.021) and variance (P = .039) in peak insulin concentrations 
between the two test days ( table 2). The intraindividual dif-
ferences and variances for the other pharmacokinetic param-
eters did not differ between the two devices (table 2 and 3). 
The inter- and intraindividual CVs were largely comparable 
for both devices, except for the interindividual CV of 
T-INS
max
, which seemed less after jet injection (Table 3).
Pharmacodynamic Endpoints
On both test days, the T-GIR
max
 was reached approximately 
40% faster when insulin was administered by jet injection 
than when this was done by conventional pen (P≤ .001 for 
both test days; Table 2, Figure 1b). The mean intraindividual 
time differences in T-GIR
max
 between the two test days were 
24.0 ± 3.5 and 27.3 ± 6.6 min for jet injection and conven-
tional administration, respectively (P = .66). The variance of 
this endpoint was about similar (P = .59) and the intraindi-
vidual CV tended to be slightly higher for jet injection than 
for conventional administration (P = .064, table 3). The aver-
age variance and intraindividual differences for the other 
pharmacodynamic endpoints did not differ between jet injec-
tion and conventional pen administration (Table 3), although 
there was a trend toward greater intraindividual CVs for jet 




This study confirmed that using a jet injector for administra-
tion of rapid-acting insulin advances the onset of insulin’s 
glucose lowering effect in comparison to insulin adminis-
tered by a conventional insulin pen. The pharmacological 
variability of insulin administered by the two devices was 
largely, but not entirely, similar. In particular, the time until 
maximal insulin concentration was less variable after jet 
injection than after conventional administration, whereas the 
maximal insulin concentration was more variable. There 
were no differences in the variability of other pharmacoki-
netic endpoints or in that of the pharmacodynamic endpoints 
between the two devices.
The disparities with regard to the variability of pharmaco-
kinetic parameters between insulin administered by jet injec-
tion or by conventional means were not mirrored by such 
differences in the more clinically relevant pharmacodynamic 
endpoints. Therefore, the play of chance cannot be excluded 
and the implications for clinical practice are probably limited. 
The intraindividual CV for the time to maximal glucose-low-
ering effect (T-GIR
max
) tended to be somewhat greater after 
jet than after conventional injection. Notably, this greater 
variability of jet injection was due to the ~40% advancement 
of insulin’s time-action profile (the denominator of the equa-
tion) rather than to an actual extension in intraindividual time 
differences (the numerator). The “predictability” of the insu-
lin effect will thus be of similar magnitude for the two devices, 
when used in daily clinical practice.
Our results extend those of two previous studies that com-
pared the variability of regular human insulin administered 
by jet injection with that by needle and syringe.9,10 One study 
investigated the variability in insulin levels after injection of 




Number of patients 15 15
Male : female 4 : 11 4 : 11
Age, years 21.3 ± 2.1 21.5 ± 2.2
BMI, kg/m2 21.6 ± 2.2 22.0 ± 2.2
Insulin dose, units 13.0 (10-17) 12.0 (11-19)
Fasting plasma glucose, mmol/l 5.4 ± 0.38 5.3 ± 0.23
Fasting plasma insulin, mU/l 10.0 ± 2.5 10.3 ± 2.8
Data are presented as mean ± SD, median and range, or number.
950 Journal of Diabetes Science and Technology 11(5)
10 units of regular insulin in 8 patients with type 1 diabetes. 
The authors found comparable intraindividual variation in 
peak insulin levels and time to peak levels for the two injec-
tion methods,9 albeit slightly higher than what we found with 
Figure 1. Mean plasma insulin levels (a) and glucose infusion rates (b) after insulin injection by the jet injector (solid line) and 
conventional pen (dashed line) on day 1 (black line) and day 2 (gray line) during the euglycemic glucose clamp.
Table 2. Pharmacodynamic and Pharmacokinetic Outcome Measurements.
Mean values Mean differences Standard deviations*
P value 
for 








, min 11.8 ± 0.7 25.2 ± 1.2§ 3.7 ± 1.0 5.7 ± 1.1 2.6 ± 0.7 4.0 ± 0.8 .21
T-INS
max
, min 31.0 ± 1.4 64.2 ± 4.9§ 7.3 ± 1.9 22.3 ± 6.3 5.2 ± 1.3 15.8 ± 4.4 .044
T-INS
AUC50%
, min 87.5 ± 3.2 122.0 ± 4.3§ 13.0 ± 3.5 14.0 ± 4.0 9.2 ± 2.5 9.9 ± 2.8 .91
C-INS
max
, mU/l 147.6 ± 7.1 94.6 ± 3.3§ 32.5 ± 6.8 14.9 ± 3.1# 23.0 ± 4.8 10.5 ± 2.2 .039
AUC
INS




, min 52.4 ± 4.3 91.2 ± 5.4§ 24.0 ± 3.5 27.3 ± 6.6 17.0 ± 2.4 19.3 ± 4.6 .59
T-GIR
AUC50%
, min 115.5 ± 3.6 144.7 ± 3.9§ 15.7 ± 3.1 11.3 ± 3.4 11.1 ± 2.2 8.0 ± 2.4 .22
GIR
max
, mg/kg/min 10.3 ± 0.6 9.2 ± 0.5 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.8 ± 0.2 .35
Gluc
total
, g 101.4 ± 6.0 108.0 ± 6.4 20.5 ± 5.0 13.9 ± 2.1 14.5 ± 3.5 9.9 ± 1.5 .93
Data are represented as mean ± SEM.
*Standard deviation of the individual mean value of the two test days.
#P < .05. §P < .001.
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aspart insulin. The second study reported comparable intra-
individual variability of both insulin effect and insulin action 
for jet injection and injection by syringes in healthy volun-
teers, based on two glucose clamps, although one of the 
clamps had a duration of only 4 hours.10 Our data are also in 
line with a study investigating the variability of insulin 
aspart. When injected by syringes in healthy volunteers, 
intraindividual CVs for pharmacodynamic parameters 
ranged from 11 to 21% and those for pharmacokinetic param-
eters from 14 to 16%.8 Finally, in a study among patients 
with type 1 diabetes, the variability in T-INS
max
 for insulin 
aspart administered by subcutaneous pump was 27%.12
The present observations should be seen in the context of 
the more rapid glucose-lowering effect of insulin after jet 
injection. We have previously shown that this reduces the 
postprandial hyperglycemic burden and advances the correc-
tion of marked hyperglycemia in patients with diabetes.3 Our 
findings suggest that these benefits can be sustained with 
repeated injections. This is important, since high variability 
in the absorption and action of insulin impacts on glucose 
variability, which not only hampers efforts to achieve opti-
mal glucose control, but also affects patient’s wellbeing and 
trust in insulin therapy.6
Limitations of our study include the parallel study design, 
which was chosen over a cross-over design for practical rea-
sons, and the small sample size, so that we cannot prove with 
statistical certainty that the pharmacological variability of 
the two devices are similar. When using the data from this 
study, power calculations show that with a power of 80% and 
a significance level of .05, 63 participants in each study arm 
would be necessary to demonstrate superiority. However, 
since the confidence intervals for the main outcome param-
eters largely overlapped (data not shown, but available upon 
request), such statistical prove may have limited relevance 
for daily clinical practice. A second limitation is that the 
healthy, young volunteers enrolled in this study do not neces-
sarily represent the majority of patients, certainly not those 
with type 2 diabetes. However, although variability of the 
insulin effect may be greater in patients with diabetes,6,13 the 
impact of clinical parameters on the pharmacokinetic vari-
ability of rapid-acting insulin has been reported small.12 
Third, we used “empty injections” as placebo, since prefilled 
insulin pens with placebo solution (Testmedium®) are not 
registered for human use. We do not think this caused a major 
bias since the same injection was used twice in each partici-
pant, an independent research nurse carried out the injections 
to assure blinding of researcher and participant, and the 
injections still looked and felt like a real insulin injection. 
Fourth, the laboratory assay we used was not specific for 
insulin aspart, which meant that it did not discriminate 
between insulin aspart and endogenous insulin. However, 
since we clamped glucose values below each individuals’ 
fasting glucose levels, we expect their endogenous insulin 
production to be suppressed and therefore negligible.14 
Finally, this study was not designed to assess the impact of 
factors relating to the site of injection, handling of the injec-
tion pen and the technique of injecting insulin on the vari-
ability of insulin.15 Notably, the jet injector differs from 
conventional pens in that specific training is required to fill 
the device with the correct amount of insulin, to remove air 
bubbles from the nozzle, and to apply the right amount of 
pressure when putting the device to the skin.
Conclusions
In conclusion, the variability in glucose-lowering effect 
is considerable, but broadly comparable for jet injection 
and conventional pen administration. When coupled with 
the approximately 40% advancement in insulin action, 
switching to jet injection may provide important clinical 
benefits for patients with diabetes on basal-bolus insulin 
regimens. Clinical studies of sufficient duration are nec-
essary to more precisely assess these benefits in daily 
clinical practice.
Table 3. Inter- and Intraindividual Coefficients of Variation for Jet Injection and Conventional Pen.
Interindividual CV (%) Intraindividual CV (%)




30.4 26.9 20.1 ± 5.4 17.5 ± 4.0 1.000
T-INS
max
24.8 41.6 15.3 ± 3.3 22.0 ± 4.6 .25
T-INS
AUC50%
20.2 19.3 9.7 ± 2.4 8.4 ± 2.2 .540
C-INS
max
26.4 18.9 15.0 ± 2.5 11.0 ± 2.2 .24
AUC
INS




37.1 25.2 34.5 ± 5.1 21.2 ± 4.6 .06
T-GIR
AUC50%
14.8 13.8 9.6 ± 2.0 5.8 ± 2.0 .08
GIR
max
31.3 28.8 5.6 ± 1.3 8.7 ± 1.8 .17
Gluc
total
29.6 32.0 13.6 ± 2.9 10.0 ± 1.7 .30
Data are represented as percentage ± SEM.




, area under the insulin concentration curve; C-INS
max
, maximal 
insulin concentration during the 6-hour study; CV, coefficient of varia-
tion; GIR, glucose infusion rate; GIR
AUC50%
, time until 50% of glucose 
disposal; GIR
max
, maximal GIR during the 6-hour study; Gluc
total
, total 
amount of glucose administered during the experiment; HbA1c, glyco-
sylated hemoglobin; RIA, radioimmunoassay; SD, standard deviation; 
SEM, standard error of the mean; T1DM, type 1 diabetes mellitus; 
T2DM, type 2 diabetes mellitus; T-GIR
AUC50%
, time of 50% of glucose 
disposal; T-GIR
max
, variability in time until maximal glucose lowering 
effect; T-INS
AUC50%
, time until 50% of insulin absorption; T-INS
max
, 
time to maximal insulin concentration; T-INS
max50%
, time until 50% of 
maximal plasma insulin value is reached.
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